Figure 2.
(A) Progression-free survival (PFS) and overall survival (OS) from the time of study enrollment of 33 patients with high-risk neuroblastoma. (B) PFS and OS from time of first HDC/SCR for 22 patients who underwent at least one HDC/SCR procedure. The number at risk at the start of year 2, 4, and 6 are given along the curves.